RFK Jr supported the MMR vaccine’s efficacy in preventing measles, but also shared unproven treatment strategies.

Following the launch of the first disease-modifying therapies for Alzheimer’s disease, a key theme at the AD/PD 2025 ...

Rhythm's Imcivree has shown benefit in a Phase III trial in patients with acquired hypothalamic obesity, leading to 19.8% ...

The CMS has opted not to move forward with a plan that would have extended Medicare coverage to obesity drugs for millions of ...

China’s NMPA has granted approval for the marketing authorisation application of Santen Pharmaceutical's Tapcom.

ABL Bio has announced a global licensing agreement with GSK, allowing the latter to develop medicines for neurodegenerative ...

The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable NSCLC ...

Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant ...

Roche outlined how digital health technologies (DHTs) provide more sensitive measures of disease progression in early ...

If preclinical findings were translated into the clinic, they could shorten the CAR-T generation lead time from two weeks to ...

The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US government to add to vaccine ...

Sanofi's oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib has gained US Food and Drug Administration ...